Whole Genome vs Exome Sequencing: Which One Do You Need?

The Question Every Genomics Project Starts With

Sara is a postdoc at a university hospital in Barcelona. Her lab has funding to sequence 200 patients with suspected rare diseases — conditions where standard genetic panels came back negative. She has the samples, the ethics approval, and the bioinformatics pipeline. What she does not have is a clear answer to the question that will shape the entire study: whole genome sequencing (WGS) or whole exome sequencing (WES)?

It is not a trivial choice. WGS costs roughly three times more per sample. With a fixed budget, choosing WGS means sequencing fewer patients. But WES only covers about 1–2% of the genome — the protein-coding regions — and Sara knows that some rare disease variants hide in regulatory regions that exome sequencing will never see.

This is the dilemma that researchers, clinicians, and increasingly consumers face every day. This guide breaks it down with the detail you need to make the right call.

What Each Technology Actually Sequences

Whole Genome Sequencing (WGS)

Whole genome sequencing reads the entire 3.2 billion base pairs of your DNA. Every exon, every intron, every promoter, every enhancer, every repetitive element, every structural variant. Nothing is excluded by design.

A standard clinical WGS run produces 30x coverage — meaning each position in your genome is read, on average, 30 times. This generates roughly 90–100 gigabytes of raw data per sample. Higher coverage (60x or even 100x) is used for specific applications like somatic mutation detection in cancer.

The key advantage is completeness. WGS captures:

• Coding variants in the ~20,000 protein-coding genes (the same territory WES covers).
• Non-coding regulatory variants in promoters, enhancers, silencers, and untranslated regions (UTRs) that control when, where, and how much protein a gene produces.
• Structural variants — deletions, duplications, inversions, and translocations larger than a few hundred base pairs — that are often missed or poorly resolved by exome sequencing.
• Intronic variants that affect RNA splicing, a mechanism responsible for an estimated 10–15% of rare disease cases.
• Mitochondrial DNA and repetitive regions like short tandem repeats (STRs), which are implicated in conditions from Huntington's disease to fragile X syndrome.

Whole Exome Sequencing (WES)

Whole exome sequencing targets only the exons — the protein-coding portions of genes. This represents roughly 1–2% of the total genome, or about 30–60 million base pairs depending on the capture kit used.

The process works by using biotinylated probes (the “capture kit”) that physically bind to exonic DNA fragments, pulling them out of the total genomic DNA like a magnet extracting needles from a haystack. Only the captured fragments are sequenced. Everything else is discarded.

A typical WES run produces 100–150x coverage of the targeted regions — significantly deeper than standard WGS — in roughly 6–8 gigabytes of data per sample. This higher per-base coverage means greater confidence in each variant call within the exome, though the tradeoff is that everything outside the capture regions is invisible.

The fundamental logic of WES rests on a powerful statistic: approximately 85% of known disease-causing mutations fall within protein-coding regions. If most pathogenic variants are in the exome, why pay to sequence the other 98% of the genome?

It is a reasonable argument. But as we will see, that 85% figure has a circular problem.

Head-to-Head Comparison

The 85% Problem

The most common argument for exome sequencing is that ~85% of known pathogenic variants are in coding regions. This is true. But it is also tautological.

For decades, the primary method of genetic investigation was Sanger sequencing of individual exons. When you only look at coding regions, you only find variants in coding regions. The databases of “known” disease variants (ClinVar, HGMD, OMIM) are overwhelmingly populated by coding mutations because that is where we have looked.

As WGS becomes more common, the proportion of disease-causing non-coding variants is growing. Recent large-scale studies have found that:

• Deep intronic variants that create cryptic splice sites account for 10–15% of previously unsolved rare disease cases when WGS is applied after negative WES.
• Regulatory variants in promoters and enhancers are increasingly recognized as causes of developmental disorders, particularly when they affect dosage-sensitive genes.
• Structural variants — large deletions, duplications, and inversions that disrupt gene regulation — are better detected by WGS and account for a meaningful fraction of rare disease diagnoses.

The real question is not “where are the known variants?” but “where might the unknown variants be?” If you are searching for something new, limiting yourself to the exome is limiting yourself to the lamppost.

When to Choose Whole Exome Sequencing

Despite its limitations, WES remains the right choice in many scenarios:

Large cohort studies with budget constraints. If you need to sequence 1,000 patients and your budget is fixed, WES lets you cover more individuals. In statistical genetics, sample size often matters more than completeness per sample. A WES study with 1,000 patients may discover more associations than a WGS study with 300.

Known Mendelian gene panels. When clinical suspicion points to a specific set of genes (e.g., cardiomyopathy panels, hereditary cancer panels), exome sequencing covers all the relevant coding regions at high depth. Many clinical labs use WES as a backbone and then computationally filter to the genes of interest.

Rapid turnaround clinical diagnostics. Smaller data volumes mean faster processing. In clinical settings where time is critical — neonatal ICUs, for instance — rapid WES can deliver results in days rather than weeks, though rapid WGS workflows are catching up.

Established bioinformatics pipelines. If your lab has validated WES pipelines and variant interpretation workflows, switching to WGS requires significant revalidation. The clinical certification process (CAP, CLIA, ISO 15189) is not trivial.

When to Choose Whole Genome Sequencing

WGS is the stronger choice when:

Previous genetic testing was negative. This is Sara's situation. When gene panels and WES have not found the answer, the variant may lie in non-coding regions, structural variants, or regions poorly covered by exome capture kits. Multiple studies show that WGS after negative WES yields an additional diagnostic rate of 10–25%.

Structural variant detection is important. If you suspect copy number variants, inversions, or translocations — common in developmental disorders, intellectual disability, and cancer — WGS provides far more uniform coverage for SV calling. Tools like Manta, DELLY, and Smoove perform significantly better on WGS data.

You want future-proof data. A WGS dataset can be reanalyzed as new disease genes and non-coding regulatory elements are discovered. WES data cannot retroactively reveal variants outside the captured regions. If you are building a biobank or longitudinal cohort, WGS is the investment that keeps giving.

Pharmacogenomics and complex trait analysis. Many pharmacogenomic variants relevant to drug metabolism are in non-coding regulatory regions or involve structural variants (like CYP2D6 gene deletions and duplications). WGS captures these more reliably than WES.

Research on non-coding biology. If your scientific question involves gene regulation, chromatin organization, or non-coding RNA, WES is fundamentally the wrong tool. You need the full genome.

Decision Flowchart

The Cost Convergence

In 2015, WGS cost approximately $1,500 per sample and WES around $500. The 3x cost difference made WES the default for most studies.

By 2026, the landscape has shifted dramatically. Illumina's NovaSeq X Plus and MGI's DNBSEQ-T20x2 have pushed WGS costs below $200 per sample at population scale (the “$200 genome”), while WES costs have plateaued around $150–$350 due to the irreducible cost of capture kit reagents.

The cost gap is narrowing. For many projects, the incremental cost of WGS over WES no longer justifies the loss of 98% of the genome. Several national genomics programs — Genomics England (100,000 Genomes Project), the All of Us Research Program (US), and Genomics Medicine Sweden — have already standardized on WGS.

Storage and compute costs remain higher for WGS (roughly 10–15x more data per sample), but cloud computing prices continue to decline, and modern analysis pipelines like Google's DeepVariant and NVIDIA's Parabricks have dramatically reduced processing time.

How AI Changes the Equation

The choice between WGS and WES is increasingly influenced by AI-powered analysis tools that can extract more information from each dataset.

Variant calling. Deep learning models like DeepVariant achieve higher accuracy on WGS data than traditional callers, particularly in difficult regions (GC-rich exons, repetitive elements, homopolymer runs). The uniform coverage of WGS plays to these models' strengths.

Non-coding variant interpretation. This is where AI is opening entirely new territory. Models trained on ENCODE, Roadmap Epigenomics, and GTEx data can now predict the regulatory impact of non-coding variants — but only if those variants are sequenced in the first place. WGS + AI interpretation is a combination that WES simply cannot match.

Structural variant detection. AI-based SV callers (like SVcnn and DeepSV) show improved sensitivity on WGS data, detecting complex rearrangements that traditional tools miss. These variants are often invisible in WES datasets.

Protein impact prediction. For coding variants (where WGS and WES overlap), protein language models like ESM-2 can predict whether a missense variant damages protein function — adding another layer of interpretation regardless of which sequencing method generated the data.

Consumer Genomics: Where Do You Fit?

If you are not a researcher but a consumer interested in your own DNA, the picture is different. Most consumer genomics services (23andMe, AncestryDNA, Nebula Genomics) use one of three approaches:

• SNP genotyping arrays — testing 600,000–900,000 pre-selected positions. This is what 23andMe and AncestryDNA provide. Not sequencing at all, but pattern matching.
• Low-pass WGS — sequencing the whole genome at very low depth (0.5–4x) and using statistical imputation to fill in the gaps. Cost-effective, but less reliable for rare variants.
• Clinical WES or WGS — full sequencing ordered through a healthcare provider, typically for a medical indication.

For most consumers, the existing data from a genotyping array is a powerful starting point. DeepDNA can analyze your raw data files from these services, applying AI models to extract insights about pharmacogenomics, nutrigenomics, and health-relevant genetic variants.

If you later obtain WES or WGS data through clinical testing, the same DeepDNA pipeline analyzes it with even greater depth — more variants, more coverage, more insights.

What About Sara?

Back to our researcher in Barcelona. Her 200 patients have already had negative gene panels. She needs to find variants that conventional approaches missed.

The answer, for Sara, is WGS. Her patients are precisely the population where the incremental value of whole genome over exome is highest: the diagnostic uplift from non-coding, structural, and deep intronic variants is 10–25% in this cohort. With WGS costs approaching WES territory, the budget difference is manageable — and a 15% additional diagnostic rate in 200 rare disease patients means potentially 30 families finally getting an answer.

For a different researcher — one running a case-control study with 5,000 samples and a hypothesis centered on coding variants in known genes — WES might still be the pragmatic choice. Context determines everything.

The Bottom Line

There is no universally correct answer. But the trend line is clear: WGS is becoming the default. As costs converge, AI-powered non-coding interpretation matures, and national programs standardize on whole genome data, the remaining advantages of WES (lower cost, smaller data footprint, faster turnaround) are eroding.

If you are starting a new project in 2026, the question is less “which should I choose?” and more “do I have a specific reason not to choose WGS?”

Whatever sequencing data you have — from a consumer genotyping chip to clinical whole genome — DeepDNA can analyze it. Our AI-powered pipeline interprets coding and non-coding variants, pharmacogenomic interactions, and health-relevant traits from your existing DNA data. Get started.

This article was created with AI assistance and reviewed by the DeepDNA editorial team.